Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin

European Journal of Pharmacology

Volumn 397, Issue 1, 2000, Pages 177-185

  Momi, Stefania ^a   Emerson, Michael ^b   Paul, William ^b   Leone, Mario ^a   Mezzasoma, Anna Maria ^a   Del Soldato, Piero ^c   Page, Clive P ^b   Gresele, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c NicOx SA   (France)

Author keywords

Endothelial factor; Hemostasis; Nitric oxide (NO); Platelet; Thrombosis

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ADRENALIN; COLLAGEN; LYSINE ACETYLSALICYLATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; LUNG EMBOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOEMBOLISM;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; ASPIRIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENOUS; LUNG; MALE; MICE; NITROARGININE; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PULMONARY ARTERY; PULMONARY EMBOLISM; RABBITS; THROMBIN; THROMBOSIS;

EID: 0034716972     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00223-5     Document Type: Article

References (38)

1. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Brit. Med. J. 308:1994;81-106.
2. Berenger F.P., Cano J.P., Rolland P.H. Antithrombogenic endothelial cell defense. Basal characteristics in cultured endothelial cells and modulation by short-term and long-term exposure to isosorbide nitrates. Circ. Res. 60:1987;612-620.
3. Bing R.J., Yamamoto T., Yamamoto M., Kakar R., Cohen A. New look at myocardial infarction:toward a better aspirin. Cardiovasc. Res. 43:1999;25-31.
4. Born G.V.R., Collins R. Aspirin versus clopidogrel: the wrong question? Lancet. 349:1997;806-807.
5. Brecher G., Cronkite E.P. Morphology and enumeration of human blood platelets. J. Appl. Physiol. 3:1950;365-375.
6. Clement M.G., Damasio M., Parravicini R., Russo V., Aguggini G. Respiratory responses to pulmonary microembolization induced by hardened rat red blood cels. Ital. J. Chest Dis. 37:1983;187-193.
7. de Belder A.J., MacAllister R., Radomski M.W., Moncada S., Vallance P.J. Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc. Res. 28:1994;691-694.
8. 2-induced vascular endothelial cell damage and respiratory smooth muscle cell contraction: inhibition by flunarizine, a Ca++-overload blocker. Arch. Intern. Pharmacodyn. Ther. 274:1985;4-23.
9. Del Soldato P., Sorrentino R., Pinto A. NO-aspirins, a class of new antinflammatory and antithrombotic agents. Trends Pharmacol. Sci. 20:1999;319-323.
10. Di Minno G., Silver J.M. Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethanol alcohol. J. Pharmacol. Exp. Ther. 225:1983;57-60.
11. Emerson M., Momi S., Paul W., Alberti P.F., Page C.P., Gresele P. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature. Thromb. Haemostasis. 81:1999;961-966.
12. Folts J.D., Schafer A.J., Loscalzo J., Willerson J.T., Muller J.E. A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials. J. Am. Coll. Cardiol. 33:1999;295-303.
13. Gresele P., Corona C., Alberti P., Nenci G.G. Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. Thromb. Haemostasis. 64:1990;80-86.
14. Gresele P., Deckmyn H., Arnout J., Nenci G.G., Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic diseases. Trends Pharmacol. Sci. 12:1991;158-163.
15. Gresele P., Momi S., Berrettini M., Nenci G.G., Schwarz H.P., Semeraro N., Colucci M. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence suggesting that activated protein C promotes the removal of intravascualr fibrin throught the inhibition of additional thrombin generation. J. Clin. Invest. 101:1998;667-676.
16. Guarneri L., Molinari A., Casacci F., Pacci E., Cerletti C., de Gaetano G. A new model of pulmonary microembolism in the mouse. J. Pharmacol. Methods. 20:1988;161-167.
17. Horobin R.W., Walter K.J. Understanding Romanowsky staining: I. The Romanowsky-Giemsa effect in blood smears. Histochemistry. 86:1987;331-336.
18. Larsson P.T., Wallen N.H., Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation. 89:1994;1951-1957.
19. 2 production. Thromb. Haemostasis. 76:1996;791-798.
20. May G.R., Herd C.M., Butler K.D., Page C.P. Radioisotopic model for investigating thromboembolism in the rabbit. J. Pharmacol. Methods. 24:1990;19-35.
21. May G.R., Crook P., Moore P.K., Page C.P. The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation of the rabbit. Br. J. Pharmacol. 102:1991;759-763.
22. Meyer B.J. Antithrombotic drugs: insights from cardiology. Cerebrovasc. Dis. 8:1998;19-27.
23. Mezzasoma A.M., Momi S., Guglielmini G., Leone M., Del Soldato P., Gresele P. Characterization of the activity of NCX 4016, a nitric oxide-releasing derivative of aspirin, on human blood platelets in vitro. Thromb. Haemostasis (Suppl.). 1999;230.
24. Moake J.L., Turner N.A., Stathopoulos N.A., Nolasco L., Hellums J.D. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF-multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood. 71:1988;1366-1374.
25. Molinari A., Guarnieri L., Pacci A., de Marchi F., Cerletti C., de Gaetano G. Mouse antithrombotic assay: the effects of Ca++ channel blockers are platelet independent. J. Pharmacol. Exp. Ther. 240:1987;623-627.
26. Momi S., Nenci G.G., Gresele P. Thrombin-induced thromboembolism in mice: a model for testing antithrombotic agents acting on coagulation/fibrinolysis. Thromb. Res. 65(Suppl. 1):1992;S162.
27. Noll G., Lusher T.F. The endothelium in acute coronary syndromes. Eur. Heart J. 19(Suppl. C):1998;C30-C38.
28. Page C.P., Paul W., Morley J. An in vivo model for studying platelet aggregation and disaggregation. Thromb. Haemostasis. 47:1982;210-213.
29. Patrono C., Coller B., Dalen J.E., Fuster V., Gent M., Harker L.A., Hirsh J., Roth G. Platelet-active drugs; the relationship among dose, effectiveness, and side effects. Chest. 114(Suppl. 5):1998;470S-488S.
30. Paul W., Gresele P., Momi S., Bianchi G., Page C.P. The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in the cerebral vasculature of rabbits. Brit. J. Pharmacol. 110:1993;1565-1571.
31. Plotkine M., Allix M., Guillou J., Boulu R. Oral administration of isosorbide dinitrate inhibits arterial thrombosis in rats. Eur. J. Pharmacol. 201:1991;115-116.
32. Riddel D.R., Owen J.S. Nitric oxide and platelet aggregation. Vitam. Horm. 57:1999;25-48.
33. Takeuchi K., Ukawa H., Konaka A., Kitamura M., Sugawa Y. Effect of nitric oxide-releasing aspirin derivative on gastric functional and ulcerogenic responses in rats: comparison with plain aspirin. J. Pharmacol. Exp. Ther. 286:1998;115-121.
34. Theroux P. Antithrombotic treatment of acute coronary syndromes. Can. J. Cardiol. 14E:1998;6E-10E.
35. Wallace J.L., Reuter B., Cicala C., McKnight W., Grisham M., Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology. 107:1994;173-179.
36. Wallace J.L., McKnight W., Del Soldato P., Baydoun A.R., Cirino G. Anti-thrombotic effects of a nitric oxide-releasing, gastric sparing aspirin derivative. J. Clin. Invest. 96:1995;2711-2718.
37. Wallace J.L., Muscara M.N., McKnight W., Dicay M., Del Soldato P., Cirino G. In vivo antithrombotic effects of a nitric oxide-releasing derivative, NCX4016. Thromb. Res. 93:1999;43-50.
38. Wolfe M.M., Lichtestein D.R., Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 340:1999;1888-1899.